Featured Research

from universities, journals, and other organizations

Treating heart attack with fat-derived stem cells may be safe in humans

Date:
November 16, 2010
Source:
American Heart Association
Summary:
Treating heart attack patients with regenerative stem cells obtained from their own fat deposits may be feasible and safe, according to a small, first-of-its-kind study. Heart muscle damage in stem cell-treated patients decreased more than half after six months; placebo-treated patients showed no change. Stem cell recipients had a greater increase in heart function, but the difference was not considered significant.

Fat cells -- liposuctioned from a patient's belly -- can safely boost heart function after a heart attack, according to a first-of-its-kind study presented at the American Heart Association's Scientific Sessions 2010.

"The study suggests that these cells can be safely obtained and infused inside the hearts of patients following an acute heart attack," said Eric (HJ) Duckers, M.D., Ph.D., lead author of the small study and head of Molecular Cardiology Laboratory at the Thoraxcenter, Erasmus University Medical Center in Rotterdam, Netherlands.

The treatment reduced the amount of damaged heart tissue, increased blood flow in the heart and improved the heart's pumping ability. These changes were not statistically significant, but the fat-derived stem cells worked as expected, Duckers said.

Duckers and colleagues recruited 11 men and three women for the prospective, double-blind, placebo-controlled APOLLO study (A Randomized Clinical Trial of AdiPOse-Derived Stem ceLLs in the Treatment of Patients With ST-Elevation myOcardial Infarction). They randomized the 14 patients -- 10 received stem cells and four got a placebo infusion. All patients had suffered a severe heart attack and had a catheter procedure to evaluate their heart damage within two to 12 hours of symptom onset.

With the patients' consent, researchers liposuctioned 200-250 cubic centimeters of fat from the abdomen of each, using a system called Celution 800 device (Cytori Tx). From the fat cells, they isolated 20 million regenerative stem cells, which took nine to 10 minutes to infuse.

With the Celution device, physicians can isolate and sometimes infuse stems cells into the heart while the original catheter is still in place. APOLLO participants received cells within 24 hours after their catheterization.

At six months follow-up, researchers found encouraging results in the treatment group:

  • Those receiving stem cells showed a 3.5-fold improvement in heart perfusion. The treatment arm also had a 5.7 percent increase in the amount of blood ejected by the left ventricle versus those receiving placebo.
  • The average size of heart muscle damage dropped from 31.6 percent to 15.4 percent in the treatment group. For the placebo arm, the average area of damage remained the same as when the patients enrolled in the study -- i.e. 24.7 percent.
  • The infused stem cells did not interfere with blood flow in the heart.
  • Stem cell therapy was not associated with ventricular arrhythmias, which are potentially fatal erratic heartbeats.
  • Two patients experienced adverse events from the liposuction procedure. Both formed a hematoma, an area of swelling filled with blood.

Although the APOLLO patients were white Europeans from the Netherlands (13) and Spain (one), "findings in the European Union population should be directly applicable to the United States population," Duckers said. "But, it's unclear whether the results would apply to non-Caucasians."

APOLLO's major limitation is its small size, and therefore its low statistical power to detect differences. This may be why researchers didn't find a significant difference between the treatment and placebo groups.

Duckers and his colleagues have initiated a phase II-III clinical trial called ADVANCE that will enroll up to 375 patients at 35 medical centers in the European Union. It will focus on acute heart attack patients with a left ventricle ejection fraction less than 45 percent. Forty percent of patients will receive 20 million stem cells; another 40 percent will get 30 million stem cells; and 20 percent will make up the placebo group.

"The primary efficacy endpoint of ADVANCE will be absolute improvement in infarct size at six months follow-up," Duckers said. "Several studies have shown that this is an excellent and more consistent predictor of survival and major adverse events (than other endpoints) in patients after an acute heart attack."

Co-authors are: Jaco Houtgraaf, M.D., Ph.D.; Robert Jan van Geuns, M.D., Ph.D.; Bas. D. van Dalen, M.D., Ph.D.; Evelien Regar, M.D., Ph.D.; Wim van der Giessen, M.D., Ph.D.; Peter de Jaegere, M.D., Ph.D.; C. Schultz, M.D., Ph.D.; Michael Martin, M.D., Ph.D.; Alexander Milstein, M.D., Ph.D.; F. J. Fernandez-Aviles, M.D., Ph.D.; and Patrick. W. Serruys, M.D., Ph.D. Author disclosures are on the abstract. Cytori Therapeutics, Inc. funded the study.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Treating heart attack with fat-derived stem cells may be safe in humans." ScienceDaily. ScienceDaily, 16 November 2010. <www.sciencedaily.com/releases/2010/11/101116111709.htm>.
American Heart Association. (2010, November 16). Treating heart attack with fat-derived stem cells may be safe in humans. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2010/11/101116111709.htm
American Heart Association. "Treating heart attack with fat-derived stem cells may be safe in humans." ScienceDaily. www.sciencedaily.com/releases/2010/11/101116111709.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Microneedle Patch Promises Painless Pricks

Microneedle Patch Promises Painless Pricks

Reuters - Innovations Video Online (Oct. 18, 2014) Researchers at The National University of Singapore have invented a new microneedle patch that could offer a faster and less painful delivery of drugs such as insulin and painkillers. Video provided by Reuters
Powered by NewsLook.com
Raw: Nurse Nina Pham Arrives in Maryland

Raw: Nurse Nina Pham Arrives in Maryland

AP (Oct. 17, 2014) The first nurse to be diagnosed with Ebola at a Dallas hospital walked down the stairs of an executive jet into an ambulance at an airport in Frederick, Maryland, on Thursday. Pham will be treated at the National Institutes of Health. (Oct. 16) Video provided by AP
Powered by NewsLook.com
Raw: Cruise Ship Returns to US Over Ebola Fears

Raw: Cruise Ship Returns to US Over Ebola Fears

AP (Oct. 17, 2014) A Caribbean cruise ship carrying a Dallas health care worker who is being monitored for signs of the Ebola virus is heading back to Texas, US, after being refused permission to dock in Cozumel, Mexico. (Oct. 17) Video provided by AP
Powered by NewsLook.com
Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

AFP (Oct. 17, 2014) All four suspected Ebola cases admitted to hospitals in Spain on Thursday have tested negative for the deadly virus in a first round of tests, the government said Friday. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins